NEWSROOM | Galderma

Galderma to pursue a new scientific partnership with L’Oréal to further advance its category leadership in dermatology

Galderma’s Relfydess™ (RelabotulinumtoxinA) receives positive decision for use in Europe

Phase III Arcadia 1 and 2 trial primary results published in The Lancet: Galderma’s nemolizumab improves key aspects of atopic dermatitis – itch, skin lesions and sleep disturbance

Galderma delivers record net sales of 2.2 billion USD and 10.8% year-on-year growth at constant currency for the first half of 2024

Galderma introduces high potency Cetaphil serums designed for sensitive skin

Shaping the future: Gerry Muhle on the technologies driving dermatology

Galderma granted key manufacturing license updates for new biologics capabilities at its center of excellence

Acne Awareness Month 2024: understanding acne scarring

Galderma launches Restylane® Volyme™ in China – one of the world’s fastest growing aesthetics markets

Galderma receives filing acceptances for nemolizumab in prurigo nodularis and atopic dermatitis in four additional countries

Galderma delivers a strong start to the year with record net sales of over 1 billion USD for the first quarter and 12.4% year-on-year growth

An organization built on uniqueness